BCL2L1 and triple-negative breast carcinoma: Chen et al. [151] showed that apatinib can enhance the anti-tumor effect of paclitaxel on triple negative breast cancer cells through the PI3K/p65/Bcl-xl signaling pathway, meaning that this combination may be a promising option for the treatment of this type of cancer.